Revolution Medicines Posts $2.29 Per Share Loss in Q1
summarizeSummary
Revolution Medicines reported a first-quarter loss of $2.29 per share. This financial update provides a current look at the company's performance, following its previously reported widened net losses for 2025 and a recent positive development where the FDA granted early access to its investigational drug, Daraxonrasib. While the company is heavily investing in its oncology pipeline, this specific Q1 loss will be a key data point for traders assessing the company's financial trajectory and burn rate. Investors will now focus on management's commentary regarding the drivers of this loss and any updated financial guidance, especially as the market weighs the costs of drug development against potential future revenue from its pipeline.
At the time of this announcement, RVMD was trading at $151.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.1B. The 52-week trading range was $34.00 to $155.70. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.